Clinical Trials Logo

Exfoliation Syndrome clinical trials

View clinical trials related to Exfoliation Syndrome.

Filter by:

NCT ID: NCT01023997 Completed - Clinical trials for Exfoliation Syndrome

Central Corneal Thickness in Glaucoma

Start date: January 2008
Phase: N/A
Study type: Observational

The purpose of this study is to compare the central corneal thickness measurement in patients with exfoliation syndrome, exfoliative glaucoma, primary open-angle glaucoma, ocular hypertension and normal controls and to evaluate the value of corneal thickness in the diagnosis and management of glaucoma.

NCT ID: NCT01022281 Completed - Clinical trials for Exfoliation Syndrome

Early Diagnosis in Glaucoma With GDxVcc

Start date: September 2007
Phase: N/A
Study type: Observational

To compare the Retina Nerve Fiber Layer thickness, measured with Scanning Laser Polarimetry in subjects with exfoliation syndrome and normal controls and to evaluate the value of scanning laser polarimetry in the early diagnosis and management of exfoliative glaucoma

NCT ID: NCT00485108 Completed - Clinical trials for Primary Open Angle Glaucoma

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

Start date: January 2007
Phase: N/A
Study type: Interventional

The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.

NCT ID: NCT00331240 Completed - Clinical trials for Primary Open Angle Glaucoma

24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the short-term (8 week) mean 24-hour intraocular pressure control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.

NCT ID: NCT00327613 Completed - Glaucoma Clinical Trials

Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma

Start date: June 2005
Phase: N/A
Study type: Observational

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by apoptotic mechanism. In earlier studies, the investigators demonstrated that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential messenger ribonucleic acid (mRNA) expression and an increased fragmentation of the deoxyribonucleic acid (DNA). Such alterations point out a relationship between cellular stress and apoptotic events. Based on the results of mRNA-expression, the investigators also expect alterations on the protein level. This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways. Thus the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with healthy controls. In addition, they will be also compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as a positive control in this study.

NCT ID: NCT00273442 Completed - Ocular Hypertension Clinical Trials

Assessing Cosopt Switch Patients

Start date: November 2005
Phase: Phase 4
Study type: Interventional

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

NCT ID: NCT00121147 Completed - Ocular Hypertension Clinical Trials

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

Start date: September 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.